Vivek Yadala

Assistant Professor

University of Arkansas for Medical Sciences

faculty

COM | Internal Med Hem-Onc

4 h-index 19 pubs 99 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Vivek Yadala investigates the outcomes and prognostic factors associated with cancer treatments, particularly in the context of immunotherapy. His research has examined the effectiveness of immune checkpoint inhibitors in lung cancer patients, with a focus on understanding the prognostic significance of specific biomarkers like the neutrophil-lymphocyte ratio and immune-related adverse events. Yadala also studies the role of radiation therapy in extensive-stage small cell lung cancer during chemotherapy and immunotherapy regimens. His work has also explored other clinical areas, including sarcoid-like reactions induced by immunotherapy and the diagnostic value of CT guidance for bone marrow biopsies. Additionally, he has investigated cases of severe immune thrombocytopenic purpura associated with COVID-19 vaccination.

Metrics

  • h-index: 4
  • Publications: 19
  • Citations: 99

Selected Publications

  • Real-World Outcomes of Immune Checkpoint Inhibitors in a Rural Appalachian Lung Cancer Cohort: Prognostic Significance of Iraes and Nlr (2025) DOI

Similar Researchers

Based on overlapping research topics